A novel PI3K inhibitor alleviates fibrotic responses in fibroblasts derived from Peyronie's plaques

Jung,Kyung  Hee; Ryu,Ye-Lim; Lee,Hee-Seung; Lee,Hyunseung; Son,Mi  Kwon; Yan,Hong  Hua; Hong,Sang-Won; Ryu,Ji-Kan; Hong,Sungwoo; Suh,Jun‑Kyu; Hong,Soon-Sun

doi:10.3892/ijo.2013.1905

A novel PI3K inhibitor alleviates fibrotic responses in fibroblasts derived from Peyronie's plaques

Authors:
- Kyung Hee Jung
- Ye-Lim Ryu
- Hee-Seung Lee
- Hyunseung Lee
- Mi Kwon Son
- Hong Hua Yan
- Sang-Won Hong
- Ji-Kan Ryu
- Sungwoo Hong
- Jun‑Kyu Suh
- Soon-Sun Hong
View Affiliations

Affiliations: Department of Biomedical Sciences, College of Medicine, Inha University, Incheon 400-712, Republic of Korea, National Research Center for Sexual Medicine, College of Medicine, Inha University, Incheon 400-712, Republic of Korea, Department of Chemistry, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 305-701, Republic of Korea
Published online on: April 16, 2013 https://doi.org/10.3892/ijo.2013.1905
Pages: 2001-2008

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Peyronie's disease (PD) is fibrosis localized in the tunica albuginea that is characterized by penile deformity and curvature. The pathogenesis of this disease remains unclear even though transforming growth factor‑β (TGF-β)/smad signalling has been reported to be associated with PD. Recent studies have shown that phosphoinositide 3-kinase (PI3K)/Akt signalling regulates fibrotic responses including collagen synthesis and cell proliferation. Thus, we synthesized HS-173, a novel PI3K inhibitor, and determined whether this compound has anti-fibrotic effects on PD-derived primary fibroblasts. In this study, we found that HS-173 inhibited the growth of fibroblasts in a dose-dependent manner and induced apoptosis. In addition, HS-173 reduced the expression of α-smooth muscle actin (α-SMA), vimentin, PAI-1, fibronectin, collagen type I, collagen IV and TGF-β-activated smad2/3 in PD-derived primary fibroblasts. HS-173 blocked the PI3K/Akt signalling pathway by decreasing the activation of Akt, mTOR and P70S6K. Our results showed that HS-173 suppressed fibrotic responses such as cell proliferation and collagen synthesis by blocking PI3K/Akt signalling in PD-derived primary fibroblasts. Our findings provide molecular insights into the potential therapeutic action of HS-173 through targeting the PI3K/Akt pathway in PD-derived fibroblasts and demonstrated that HS-173 could be used as a pharmacological agent for treating other fibrotic diseases.

View Figures

View References

1	Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B and Engelmann U: The prevalence of Peyronie’s disease: results of a large survey. BJU Int. 88:727–730. 2001.
2	Ralph D, Gonzalez-Cadavid N, Mirone V, Perovic S, Sohn M, Usta M and Levine L: The management of Peyronie’s disease: evidence-based 2010 guidelines. J Sex Med. 7:2359–2374. 2010.
3	Mulhall JP, Creech SD, Boorjian SA, Ghaly S, Kim ED, Moty A, Davis R and Hellstrom W: Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening. J Urol. 171:2350–2353. 2004.PubMed/NCBI
4	Dean RC and Lue TF: Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am. 32:379–395. 2005. View Article : Google Scholar : PubMed/NCBI
5	Gonzalez-Cadavid NF and Rajfer J: Mechanisms of disease: new insights into the cellular and molecular pathology of Peyronie’s disease. Nat Clin Pract Urol. 2:291–297. 2005.PubMed/NCBI
6	Haag SM, Hauck EW, Szardening-Kirchner C, Diemer T, Cha ES, Weidner W and Eickelberg O: Alterations in the transforming growth factor (TGF)-beta pathway as a potential factor in the pathogenesis of Peyronie’s disease. Eur Urol. 51:255–261. 2007.PubMed/NCBI
7	Domes T, De Young L, O’Gorman DB, Gan BS, Bella AJ and Brock G: Is there a role for proteomics in Peyronie’s disease? J Sex Med. 4:867–877. 2007.PubMed/NCBI
8	El-Sakka AI, Hassoba HM, Chui RM, Bhatnagar RS, Dahiya R and Lue TF: An animal model of Peyronie’s-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J Urol. 158:2284–2290. 1997.
9	Assinder SJ, Dong Q, Kovacevic Z and Richardson DR: The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. Biochem J. 417:411–421. 2009. View Article : Google Scholar : PubMed/NCBI
10	Danielpour D: Functions and regulation of transforming growth factor-beta (TGF-beta) in the prostate. Eur J Cancer. 41:846–857. 2005. View Article : Google Scholar : PubMed/NCBI
11	Cantley LC: The phosphoinositide 3-kinase pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
12	Carracedo A and Pandolfi PP: The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene. 27:5527–5541. 2008. View Article : Google Scholar : PubMed/NCBI
13	Andre E, Gazzieri D, Bardella E, Ferreira J, Mori MA, Saul VV, Bader M, Calixto JB, De Giorgio R, Corinaldesi R, Geppetti P and Trevisani M: Expression and functional pharmacology of the bradykinin B1 receptor in the normal and inflamed human gallbladder. Gut. 57:628–633. 2008. View Article : Google Scholar : PubMed/NCBI
14	Reif S, Lang A, Lindquist JN, Yata Y, Gabele E, Scanga A, Brenner DA and Rippe RA: The role of focal adhesion kinase-phosphatidylinositol 3-kinase-akt signaling in hepatic stellate cell proliferation and type I collagen expression. J Biol Chem. 278:8083–8090. 2003. View Article : Google Scholar : PubMed/NCBI
15	Gentilini A, Marra F, Gentilini P and Pinzani M: Phosphatidylinositol-3 kinase and extracellular signal-regulated kinase mediate the chemotactic and mitogenic effects of insulin-like growth factor-I in human hepatic stellate cells. J Hepatol. 32:227–234. 2000. View Article : Google Scholar
16	Kulik G, Klippel A and Weber MJ: Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol. 17:1595–1606. 1997.PubMed/NCBI
17	Kim AH, Khursigara G, Sun X, Franke TF and Chao MV: Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol. 21:893–901. 2001. View Article : Google Scholar : PubMed/NCBI
18	Coffer PJ, Jin J and Woodgett JR: Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J. 335(Pt 1): 1–13. 1998.PubMed/NCBI
19	Lee H, Jung KH, Jeong Y, Hong S and Hong SS: HS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis. Cancer Lett. 328:152–159. 2013. View Article : Google Scholar : PubMed/NCBI
20	Hong S, Lee S, Kim B, Lee H and Hong SS: Discovery of new azaindole-based PI3Kalpha inhibitors: apoptotic and antiangiogenic effect on cancer cells. Bioorg Med Chem Lett. 20:7212–7215. 2010. View Article : Google Scholar : PubMed/NCBI
21	Piao S, Choi MJ, Tumurbaatar M, Kim WJ, Jin HR, Shin SH, Tuvshintur B, Yin GN, Song JS, Kwon MH, Lee SJ, Han JY, Kim SJ, Ryu JK and Suh JK: Transforming growth factor (TGF)-beta type I receptor kinase (ALK5) inhibitor alleviates profibrotic TGF-beta1 responses in fibroblasts derived from Peyronie’s plaque. J Sex Med. 7:3385–3395. 2010.PubMed/NCBI
22	LaRochelle JC and Levine LA: A survey of primary-care physicians and urologists regarding Peyronie’s disease. J Sex Med. 4:1167–1173. 2007.PubMed/NCBI
23	Sasso F, Gulino G, Falabella R, D’Addessi A, Sacco E, D’Onofrio A and Bassi PF: Peyronie’s disease: lights and shadows. Urol Int. 78:1–9. 2007.
24	Shindel AW and Lue TF: Peyronie’s disease: past, present, future? Curr Urol Rep. 9:425–427. 2008.
25	Hauck EW, Diemer T, Schmelz HU and Weidner W: A critical analysis of nonsurgical treatment of Peyronie’s disease. Eur Urol. 49:987–997. 2006.PubMed/NCBI
26	Son G, Hines IN, Lindquist J, Schrum LW and Rippe RA: Inhibition of phosphatidylinositol 3-kinase signaling in hepatic stellate cells blocks the progression of hepatic fibrosis. Hepatology. 50:1512–1523. 2009. View Article : Google Scholar : PubMed/NCBI
27	Conte E, Fruciano M, Fagone E, Gili E, Caraci F, Iemmolo M, Crimi N and Vancheri C: Inhibition of PI3K prevents the proliferation and differentiation of human lung fibroblasts into myofibroblasts: the role of class I P110 isoforms. PLoS One. 6:e246632011. View Article : Google Scholar : PubMed/NCBI
28	Abdel-Hamid IA and Anis T: Peyronie’s disease: perspectives on therapeutic targets. Expert Opin Ther Targets. 15:913–929. 2011.
29	Bobustuc GC, Smith JS, Maddipatla S, Jeudy S, Limaye A, Isley B, Caparas ML, Constantino SM, Shah N, Baker CH, Srivenugopal KS, Baidas S and Konduri SD: MGMT inhibition restores ERalpha functional sensitivity to antiestrogen therapy. Mol Med. 18:913–929. 2012. View Article : Google Scholar : PubMed/NCBI
30	Anderson MS, Shankey TV, Lubrano T and Mulhall JP: Inhibition of Peyronie’s plaque fibroblast proliferation by biologic agents. Int J Impot Res. 12(Suppl 3): S25–S31. 2000.PubMed/NCBI
31	Mulhall JP, Nicholson B, Pierpaoli S, Lubrano T and Shankey TV: Chromosomal instability is demonstrated by fibroblasts derived from the tunica of men with Peyronie’s disease. Int J Impot Res. 16:288–293. 2004.PubMed/NCBI
32	Elmore S: Apoptosis: a review of programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
33	Mikulec AA, Hanasono MM, Lum J, Kadleck JM, Kita M and Koch RJ: Effect of tamoxifen on transforming growth factor beta1 production by keloid and fetal fibroblasts. Arch Facial Plast Surg. 3:111–114. 2001. View Article : Google Scholar : PubMed/NCBI
34	He Z, Gao Y, Deng Y, Li W, Chen Y, Xing S, Zhao X, Ding J and Wang X: Lipopolysaccharide induces lung fibroblast proliferation through Toll-like receptor 4 signaling and the phosphoinositide3-kinase-Akt pathway. PLoS One. 7:e359262012. View Article : Google Scholar : PubMed/NCBI
35	Voloshenyuk TG, Landesman ES, Khoutorova E, Hart AD and Gardner JD: Induction of cardiac fibroblast lysyl oxidase by TGF-beta1 requires PI3K/Akt, Smad3, and MAPK signaling. Cytokine. 55:90–97. 2011. View Article : Google Scholar : PubMed/NCBI
36	Xia H, Khalil W, Kahm J, Jessurun J, Kleidon J and Henke CA: Pathologic caveolin-1 regulation of PTEN in idiopathic pulmonary fibrosis. Am J Pathol. 176:2626–2637. 2010. View Article : Google Scholar : PubMed/NCBI
37	Marra F, Gentilini A, Pinzani M, Choudhury GG, Parola M, Herbst H, Dianzani MU, Laffi G, Abboud HE and Gentilini P: Phosphatidylinositol 3-kinase is required for platelet-derived growth factor’s actions on hepatic stellate cells. Gastroenterology. 112:1297–1306. 1997.
38	Foukas LC, Berenjeno IM, Gray A, Khwaja A and Vanhaesebroeck B: Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc Natl Acad Sci USA. 107:11381–11386. 2010. View Article : Google Scholar : PubMed/NCBI